A large international investment in hereditary retinal diseases
Jun 06, 2023

The path of AAVantgarde Bio, the Tigem spin-off dedicated to the development of gene therapies for hereditary diseases of the retina, continues at full speed! The company, founded in 2021 thanks to the Sofinnova-Telethon fund, has in fact announced that it has obtained a 61 million euro from three major international investment companies: Atlas Venture, Forbion and Longwood. AAVantgarde Bio will work to bring an innovative gene therapy approach born in the Telethon laboratories to the clinic.

Read More